Restoring fertility in premature ovarian insufficiency: Targeting the ovarian stroma with antifibrotic drugs. [PDF]
Clin Transl MedClinical and Translational Medicine, Volume 16, Issue 10, October 2026.
Zhao Y, Liu K.
europepmc +2 more sources
Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD [PDF]
, 2022 BACKGROUND AND OBJECTIVE: Finerenone reduces the risk of kidney failure in patients with chronic kidney disease and type 2 diabetes. Changes in the urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) are surrogates ...
Goulooze, Sebastiaan Camiel +14 more
core +1 more source
Cardiorenal benefits of finerenone: protecting kidney and heart [PDF]
, 2023 Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors.
Valle, Alfonso +19 more
core +1 more source
Administration of finerenone in chronic kidney disease [PDF]
, 2022 Spironolactone is a first-generation and non-selective mineralocorticoid receptor antagonist (MRA). It is extensively well-studied and recommended due to increased accessibility for patients.
Elham Emami +4 more
core +2 more sources
Feasibility of Decentralised Response-Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease. [PDF]
Diabetes Obes MetabABSTRACT Aims To assess the feasibility of a decentralised response‐guided trial and to characterise urinary albumin‐to‐creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2,
Beernink JM, Laverman GD, Heerspink HJL.
europepmc +2 more sources
, 2022 Background: In patients with type 2 diabetes (T2D), risks of cardiovascular mortality and heart failure (HF) increase with decreasing kidney function (estimated glomerular filtration rate [eGFR]) and increasing albuminuria (urine albumin-to-creatinine ...
Lambelet, Marc +10 more
core +3 more sources
Real-World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study (MEDFINE-RWD). [PDF]
Diabetes Obes MetabABSTRACT Aim Although finerenone has shown efficacy in randomized trials, evidence from routine clinical practice remains limited. We aimed to assess the real‐world effectiveness and safety of finerenone in people with type 2 diabetes (PWT2D) and chronic kidney disease (CKD), with a particular focus on residual cardiorenal risk as reflected by changes ...
Moreno-Pérez O +13 more
europepmc +2 more sources
The Role of Finerenone in the Management of Diabetic Nephropathy [PDF]
Diabetes Therapy, 2021 Diabetic nephropathy (DN) is the leading cause of chronic kidney disease. Even though mineralocorticoid receptor antagonists (MRA) induce incremental reductions in urine albumin excretion when added to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, this combination is infrequently used because of an increased risk of ...
Stavroula Veneti, Konstantinos Tziomalos
openaire +2 more sources
Frontiers in Pharmacology, 2022 Background: Chronic kidney disease (CKD) is a global public health issue. In recent years, the effectiveness of finerenone for treatment of CKD has been the subject of considerable debate.
Ming-Zhu Zhang +9 more
doaj +1 more source
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis
Kidney Medicine, 2023 Rationale & Objective: In FIDELITY, finerenone improved cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes. This analysis explores the efficacy and safety of finerenone in Hispanic patients.
Sylvia E. Rosas +15 more
doaj +1 more source